Breaking News

Tweet TWEET

Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014

 Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the
                    2014 Diabetes Summit on April 24, 2014

Podium Presentation Highlighting Safety and Efficacy Data to be Presented by
the Company's CSO, Dr. Miriam Kidron

PR Newswire

JERUSALEM, March 3, 2014

JERUSALEM, March 3, 2014 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
clinical-stage pharmaceutical company focused on the development of oral drug
delivery systems, announced today that it will be presenting detailed results
from its recently completed Phase 2a FDA trial on ORMD-0801, its orally
ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from
April 23-25, 2014, in Boston, Massachusetts, USA.

Oramed's Chief Scientific Officer, Dr. Miriam Kidron, will be presenting the
data during the New Therapeutic Targets for Diabetes session. This was a
randomized, double-blind, placebo-controlled Phase 2a study designed to assess
the safety and tolerability of multiple bedtime doses of the ORMD-0801 oral
insulin formulation in adult Type 2 diabetes patients inadequately controlled
with diet alone or diet and metformin. Preliminary results were announced by
the company on January 30^th of this year.

Presentation Details

Title:The Tolerability and Efficacy of Oral Insulin in Type 2 Diabetes
Patients: A Pilot Clinical Study
Time:3:15 on April 24^th 2014

Location:Hyatt Regency Cambridge, MA

The presentation slides will be available on the Company's website
simultaneous with the Diabetes Summit.

About ORMD-0801 Oral Insulin

Oramed's ORMD-0801 is an orally ingestible insulin capsule for the early
stages of type 2 diabetes, when it can still slow the rate of degeneration of
the disease by providing additional insulin to the body and allowing
pancreatic respite. Moreover, orally administered insulin has the potential
benefit of enhanced patient compliance at this crucial stage as well as the
advantage of mimicking insulin's natural location and gradients in the body by
first passing through the liver before entering the bloodstream. For more
information on ORMD-0801, please visit: http://oramed.com.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's Protein Oral Delivery (POD^[^TM^]) technology is
based on over 30 years of research by top research scientists
atJerusalem'sHadassah Medical Center. Oramed is seeking to revolutionize the
treatment of diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on
patients with type 2 diabetes (T2DM) under an Investigational New Drug
application with the U.S. Food and Drug Administration, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog). Oramed is also moving forward
with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The
company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 and other federal securities laws. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates" and
similar expressions or variations of such words are intended to identify
forward-looking statements. For example, we are using forward-looking
statements when we discuss our clinical trials, including the expected timing,
the anticipated safety of ORMD-0801 and revolutionizing the treatment of
diabetes with our products. These forward-looking statements are based on the
current expectations of the management of Oramed only, and are subject to a
number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost, and results
of clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product candidates;
competition from other pharmaceutical or biotechnology companies; and our
ability to obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the following
factors, among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in technology and
market requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our technology
as we progress further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally good results
in real settings; our patents may not be sufficient; and final that products
may harm recipients, all of which could cause the actual results or
performance of Oramed to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Oramed
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman-Guiloff
Office: +972-2-566-0001
US: +1-718-831-2512
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
 
Press spacebar to pause and continue. Press esc to stop.